Oracle stock falls after report reveals thin margins in AI cloud business
Director Harpreet Grewal of Penumbra Inc (NYSE:PEN) sold 186 shares of common stock on September 2, 2025, at a price of $272.19, for a total transaction value of $50,627. The medical devices company, currently valued at $10.88 billion, trades near its 52-week high of $310. According to InvestingPro analysis, the stock appears to be trading above its Fair Value, with a P/E ratio of 72.5x. Following the transaction, Grewal directly owns 8,888 shares, a portion of which is subject to vesting
The sale was executed under a prearranged Rule 10b5-1 trading plan
In other recent news, Penumbra Inc . reported its second-quarter 2025 earnings, surpassing both earnings per share and revenue forecasts. The company posted an EPS of $0.86, exceeding the anticipated $0.83, and achieved a revenue of $339.5 million, above the expected $327.77 million. Following these results, UBS raised its price target for Penumbra to $335 from $330, maintaining a Buy rating due to the solid growth reflected in the quarterly results. RBC Capital, while lowering its price target slightly to $325 from $330, maintained an Outperform rating, noting strong peripheral vascular growth and above-market performance in the stroke business. Evercore ISI initiated coverage on Penumbra with an Outperform rating, highlighting the potential of the STORM PE product and a favorable growth outlook. Additionally, Penumbra announced the promotion of Shruthi Narayan to President, effective September 1, 2025, as she continues to report to CEO Adam Elsesser. Narayan, with a long history in the medical device industry, has been with Penumbra since 2013. These developments reflect a period of strategic growth and leadership transition for the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.